Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of GBP 752.34 million. The enterprise value is 385.69 million.

Market Cap	752.34M
Enterprise Value	385.69M

Important Dates

The next estimated earnings date is Friday, August 8, 2025.

Earnings Date	Aug 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	161.97M
Shares Outstanding	n/a
Shares Change (YoY)	+41.51%
Shares Change (QoQ)	+10.85%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	136.65M

Valuation Ratios

The trailing PE ratio is 2.03.

PE Ratio	2.03
Forward PE	n/a
PS Ratio	0.77
PB Ratio	-12.85
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.13, with an EV/FCF ratio of -2.53.

EV / Earnings	1.04
EV / Sales	0.42
EV / EBITDA	1.13
EV / EBIT	1.25
EV / FCF	-2.53

Financial Position

The company has a current ratio of 2.06

Current Ratio	2.06
Quick Ratio	1.78
Debt / Equity	n/a
Debt / EBITDA	0.49
Debt / FCF	-1.16
Interest Coverage	19.50

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	19.97%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	48.55%
Revenue Per Employee	1.02M
Profits Per Employee	389,188
Employee Count	952
Asset Turnover	0.95
Inventory Turnover	40.12

Taxes

In the past 12 months, Novavax has paid 7.60 million in taxes.

Income Tax	7.60M
Effective Tax Rate	2.01%

Stock Price Statistics

The stock price has decreased by -48.78% in the last 52 weeks. The beta is 2.77, so Novavax's price volatility has been higher than the market average.

Beta (5Y)	2.77
52-Week Price Change	-48.78%
50-Day Moving Average	6.77
200-Day Moving Average	8.51
Relative Strength Index (RSI)	43.86
Average Volume (20 Days)	98,302

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.93

Income Statement

In the last 12 months, Novavax had revenue of GBP 971.33 million and earned 370.51 million in profits. Earnings per share was 2.30.

Revenue	971.33M
Gross Profit	566.99M
Operating Income	327.25M
Pretax Income	378.11M
Net Income	370.51M
EBITDA	361.84M
EBIT	327.25M
Earnings Per Share (EPS)	2.30

Full Income Statement

Balance Sheet

The company has 566.16 million in cash and 176.98 million in debt, giving a net cash position of 389.18 million.

Cash & Cash Equivalents	566.16M
Total Debt	176.98M
Net Cash	389.18M
Net Cash Per Share	n/a
Equity (Book Value)	-58.55M
Book Value Per Share	-0.36
Working Capital	345.09M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -146.45 million and capital expenditures -5.73 million, giving a free cash flow of -152.17 million.

Operating Cash Flow	-146.45M
Capital Expenditures	-5.73M
Free Cash Flow	-152.17M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 58.37%, with operating and profit margins of 33.69% and 38.14%.

Gross Margin	58.37%
Operating Margin	33.69%
Pretax Margin	38.93%
Profit Margin	38.14%
EBITDA Margin	37.25%
EBIT Margin	33.69%
FCF Margin	n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-41.51%
Shareholder Yield	n/a
Earnings Yield	49.25%
FCF Yield	-20.23%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 10, 2019. It was a reverse split with a ratio of 0.05.

Last Split Date	May 10, 2019
Split Type	Reverse
Split Ratio	0.05

Scores

Novavax has an Altman Z-Score of -1.71 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.71
Piotroski F-Score	5